Sofinnova Partners Secures €165 Million for Biovelocita II
Funding | Mar 18, 2025 | CDP Venture Capital
Sofinnova Partners, a major player in venture capital investment, has successfully raised €165 million for its Biovelocita II fund. The fundraising involves significant backing from prominent global pharmaceutical companies, underscoring confidence in the fund's strategy to accelerate biotech innovation across Europe. Biovelocita II aims to invest in burgeoning biotech startups, supporting their development and growth in the sector. CDP Venture Capital is among the supportive investors. This accomplishment highlights the ongoing commitment to driving innovation and scientific advancement within the biotech industry.
Sectors
- Biotechnology
- Venture Capital
- Pharmaceuticals
Geography
- Europe – The Biovelocita II fund is dedicated to investing in and accelerating biotech innovation within Europe.
Industry
- Biotechnology – The fund focuses on accelerating biotech innovation by investing in promising startups operating within the biotech sector.
- Venture Capital – Sofinnova Partners is a venture capital firm raising significant funds to support biotech innovation and startups.
- Pharmaceuticals – The funding round secured backing from global pharmaceutical companies, indicating their involvement in fostering biotech advancements.
Financials
- €165 million – The amount raised by Sofinnova Partners for the Biovelocita II fund.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Sofinnova Partners | Fundraiser and Investment Manager | Company | Sofinnova Partners is a venture capital firm that has raised €165 million for its Biovelocita II fund. |
| CDP Venture Capital | Investor | Company | CDP Venture Capital is one of the investors backing the Biovelocita II fund. |
| Global Pharmaceutical Companies | Investors | Company | Leading global pharmaceutical companies have supported the Biovelocita II fund to foster biotech innovation. |